Himachal Newsline
Tuesday, March 28, 2023
No Result
View All Result
  • Home
  • Himachal Pradesh News
  • India
    • National
    • State News
  • World
  • Business
  • Education
  • Entertainment
  • Lifestyle
    • Health & Fitness
    • Fashion & Beauty
    • Travel
    • Food
    • Photography
  • Tech
    • App News
  • Auto
  • Others
    • Sports
    • Agriculture
    • Science
    • Astrology
    • Finance/Money
    • Press Release
    • Social Work
    • Religion
Himachal Newsline
No Result
View All Result

AustralaSian COVID-19 Trial opens in India

Himachal Newsline Desk by Himachal Newsline Desk
March 1, 2021
in Health & Fitness, National
0 0
0
Share on FacebookShare on Twitter

New Delhi: AustralaSian COVID-19 Trial (ASCOT) has been expanded into India, with the first patients recruited last week to the first two sites, Christian Medical College and Hospital Ludhiana in Punjab and Sterling Multispecialty Hospital in Pune, Maharashtra. Australasia is a region that comprises Australia, New Zealand, and some neighboring islands.

ASCOT has partnered with the George Institute for Global Health to oversee the trial in India given its substantial experience operating clinical trials in the country with a presence in 21 states.George Institute for Global Health is an independent medical research institute headquartered in Australia with offices in China, India and the United Kingdom.

RelatedPosts

Japan-based Toyota Tsusho Corporation and Tokai Corp Partner to Launch Valabhi Hospital Services

Japan-based Toyota Tsusho Corporation and Tokai Corp Partner to Launch Valabhi Hospital Services

March 20, 2023
Do rare Diseases account for the economic burden on India?

Do rare Diseases account for the economic burden on India?

March 20, 2023

ASCOT aims to discover which existing treatments are most effective in patients hospitalised with COVID-19 and whether they will prevent patients deteriorating to the point of needing a ventilator in the Intensive Care Unit.

ASCOT has partnered with the George Institute for Global Health to oversee the trial in India given its substantial experience operating clinical trials in the country with a presence in 21 states.

ASCOT Principal Investigator, Associate Professor Steven Tong, a Royal Melbourne Hospital infectious diseases clinician and co-lead of clinical research at the Doherty Institute said that while ASCOT began as an Australian and New Zealand trial, expanding internationally to allow more widespread access to investigational treatments was crucial.

“A key principle of the trial is equity in terms of access to experimental treatments that could potentially have benefits for patients,” Associate Professor Tong said.

“The ASCOT Management Team and Leadership Group recognised early in the course of the trial that for it to have generalisability, external validity and be adequately powered, it would need to be expanded to international sites.”

India, like many other middle and low-income countries, is facing a severe epidemic of COVID-19. The number of patients with COVID-19 in India remains significantly higher than in Australia and New Zealand, and access to experimental treatments is limited.

Bala Venkatesh, Professorial Fellow at the George Institute for Global Health, said that while there are other ongoing clinical trials in India for COVID-19, the novel combinations of treatments included in ASCOT will provide greater opportunities to patients for accessing new treatments.

“We are confident that the study questions being asked are of priority to Indian patients and participating trial sites, and feasible to address in India,” said Professor Venkatesh.

One new treatment that’s recently been added to ASCOT is Nafamostat, which in laboratory experiments has shown to block SARS-COV-2 from entering human cells and be far more potent than Remdesivir.

“Nafamostat is mainly used in Korea and Japan as a treatment for acute pancreatitis and some blood clotting conditions. Of all drugs with potency data from laboratory studies using human cell lines, nafamostat appears to be the most potent against SARS-CoV-2 and maybe the only drug where blood concentrations almost always exceed levels required to stop the virus from replicating,” explained Associate Professor Tong.

“It is also likely that Nafamostat will reach high levels in the lungs where the SARS-CoV-2 virus causes so much of its problems. What’s more, it has a favourable safety profile.”

The ASCOT Steering Committee recently made the decision to cease enrolment into the convalescent plasma arm of the trial following a media release issued by the UK’s RECOVERY trial, which reported no benefit to patients compared with standard of care. (India Science Wire)

Tags: ASCOTAustralaSianChristian Medical College and HospitalClinical TrialCOVID-19Sterling Multispecialty Hospital
Previous Post

Dr. Harsh Vardhan dedicates two new databases to the nation

Next Post

Synthesis of agonist molecule by CSIR-IICT for COVAXIN

Himachal Newsline Desk

Himachal Newsline Desk

Related Posts

Japan-based Toyota Tsusho Corporation and Tokai Corp Partner to Launch Valabhi Hospital Services
Health & Fitness

Japan-based Toyota Tsusho Corporation and Tokai Corp Partner to Launch Valabhi Hospital Services

March 20, 2023
Do rare Diseases account for the economic burden on India?
Health & Fitness

Do rare Diseases account for the economic burden on India?

March 20, 2023
zPlus.care for all your healthcare needs
Health & Fitness

zPlus.care for all your healthcare needs

March 17, 2023
Narayana Health’s multi-location campaigns emphasize on Awareness and honour the spirit of Cancer Survivors
Health & Fitness

Narayana Health’s multi-location campaigns emphasize on Awareness and honour the spirit of Cancer Survivors

March 1, 2023
Dr. Gautam Allahbadia takes us through the IVF journey 
Health & Fitness

Dr. Gautam Allahbadia takes us through the IVF journey 

February 23, 2023
CanSupport Walk for Life – Stride Against Cancer
Health & Fitness

CanSupport Walk for Life – Stride Against Cancer

February 18, 2023
Next Post

Synthesis of agonist molecule by CSIR-IICT for COVAXIN

Sublethal exposure study of lead (Pb) on black clams to provide early warning information on marine pollution

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Child Help Foundation Organized Activities and Campaigns for the Upliftment of women on International Women’s Day March 27, 2023
  • Sakif Shamim Person of the Year March 27, 2023
  • “The beautiful mosque, built by The IB Group, will be known as Azeez Masjid” March 27, 2023
  • SATHYAPRIYA MANIAN: Empowering Individuals and Changing Lives with a Holistic Approach March 27, 2023
  • Anupam V Joshi of WAE Limited bags “The Most Promising Business Leaders of Asia” award March 24, 2023

Categories

  • Agriculture (11)
  • App News (13)
  • Astrology (3)
  • Auto (15)
  • Business (442)
  • Education (100)
  • Entertainment (157)
  • Fashion & Beauty (33)
  • Finance/Money (25)
  • Food (17)
  • Himachal Pradesh News (1)
  • India (2)
  • Lifestyle (428)
    • Health & Fitness (168)
    • Photography (5)
    • Travel (24)
  • National (119)
  • Politics (3)
  • Press Release (5)
  • Religion (6)
  • Science (94)
  • Social Work (33)
  • Sports (38)
  • State News (69)
  • Tech (61)
  • World (10)

Categories

  • Agriculture
  • App News
  • Astrology
  • Auto
  • Business
  • Education
  • Entertainment
  • Fashion & Beauty
  • Finance/Money
  • Food
  • Health & Fitness
  • Himachal Pradesh News
  • India
  • Lifestyle
  • National
  • Photography
  • Politics
  • Press Release
  • Religion
  • Science
  • Social Work
  • Sports
  • State News
  • Tech
  • Travel
  • World

Recent News

  • Child Help Foundation Organized Activities and Campaigns for the Upliftment of women on International Women’s Day
  • Sakif Shamim Person of the Year
  • “The beautiful mosque, built by The IB Group, will be known as Azeez Masjid”
  • SATHYAPRIYA MANIAN: Empowering Individuals and Changing Lives with a Holistic Approach
  • Anupam V Joshi of WAE Limited bags “The Most Promising Business Leaders of Asia” award
  • About Us
  • Advertise
  • Contact Us
  • DMCA
  • Follow on Google News

© 2022 Himachal Newsline

No Result
View All Result
  • About Us
  • Advertise
  • Contact Us
  • DMCA
  • Home
  • Privacy Policy

© 2022 Himachal Newsline

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In